Shares of Juno Therapeutics Inc. (Nasdaq: JUNO) soared $5.75 to close at $36.48 after rival cell therapy developer Kite Pharma (Nasdaq: KITE) announced its acquisition by Gilead (Nasdaq: GILD). Kite Pharma stock leaped $38.95 to close at $178.05 while shares of Gilead rose 90 cents to close at $74.69.
Juno Therapeutics stock soars on Kite Pharma acquisition
August 28, 2017 at 17:34 PM EDT
